There are number of new and emerging antiretroviral agents for the treatment of HIV. Dr Amesika Nyaku (Rutgers New Jersey Medical School, Newark, NJ, USA) discusses different antiretroviral therapies, including long-acting cabotegravir and long-acting rilivirine, the use of fostemsavir and in whom this treatment benefits most, and management of missed doses.
View more content from Dr Amesika Nyaku: Future directions in HIV research
The presentation entitled: ‘New Antiretroviral Agents and When to Use Them’ was presented at the American Conference for the Treatment of HIV (ACTHIV), May 5-7, 2022.
- What is the mechanism of action of the long-acting cabotegravir and long-acting rilpivirine? (0:16)
- What are the cautions/contraindications of these drugs? (1:33)
- How should missed doses be managed? (3:28)
- Could you tell us a little about fostemsavir and the patients most likely to benefit from it? (6:31)
Disclosures: Amesika Nyaku has nothing to disclose in relation to this video interview.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.
Share this Video
Related Videos In HIV
Updated HIV primary care guidelines: Mamta Jain, ACTHIV 2023
Updated HIV primary care guidelines provide evidence-based and standardized approaches to manage individuals living with HIV, addressing their unique needs and challenges. By following these guidelines, healthcare providers can enhance patient outcomes and stay abreast of the latest research and treatment advancements in HIV care. In this interview, we speak with Dr Mamta Jain (UT […]
Managing liver complications and drug-drug interactions in HBV-HIV co-infection: ACTHIV 2023 with Jessie Torgersen
Liver complications and drug-drug interactions in HBV viremia in HIV patients are common, so it is important to consider complications and follow appropriate guidelines for patients when prescribing treatment. In this interview, we speak with Dr Jessie Torgersen (University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA) to explore considerations for healthcare professionals, including liver complications […]
HIV-HBV co-infection screening and monitoring guidelines: ACTHIV 2023, Jessie Torgersen
Screening and managing HIV-hepatitis B virus (HBV) co-infection is important due to increased risks in patients, therefore it is important to ensure standard practices involve comprehensive assessment, including serological testing and liver function evaluation, and healthcare professionals follow guidelines for regular monitoring to assess disease progression and treatment response. In this interview, we speak with […]